JustWire.io

Tue, 30.09.2025 Valneva SE

Saint-Herblain (France), September 30, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data four years after vaccination with a single dose of its chikungunya vaccine IXCHIQ®. The results are in line with Valneva’s expectations for this vaccine, confirming a strong and...

Newsfeed

Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ® | Valneva SE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN | Valneva SE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN | Valneva SE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN | Valneva SE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN | Valneva SE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN | Valneva SE

VALNEVA Declaration of shares and voting rights: August 31, 2025 | Valneva SE

Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate | Valneva SE

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S. | Valneva SE

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older | Valneva SE

Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates | Valneva SE

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information | Valneva SE

Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly | Valneva SE

VALNEVA Declaration of shares and voting rights: June 30, 2025 | Valneva SE

Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus | Valneva SE

Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance | Valneva SE

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update | Valneva SE

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States | Valneva SE

VALNEVA Declaration of shares and voting rights: April 30, 2025 | Valneva SE

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates | Valneva SE

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities | Valneva SE

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers | Valneva SE

Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2 | Valneva SE

Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA | Valneva SE

Valneva Renews its Sales Agreement in connection with its Existing At-the-Market (ATM) Program | Valneva SE

Valneva Announces Filing of 2024 Universal Registration Document and US Form 20-F | Valneva SE

Valneva Responds to French Government’s Call for Vaccine Supply of IXCHIQ® against Chikungunya Outbreak in La Réunion | Valneva SE

Valneva Reports Full Year 2024 Results and Provides Business Updates and Outlook | Valneva SE

VALNEVA Declaration of shares and voting rights: February 28, 2025 | Valneva SE

Valneva to Present at Upcoming TD Cowen and Van Lanschot Kempen Healthcare Investor Conferences | Valneva SE

Valneva Reports Preliminary Unaudited 2024 Revenue and Cash and Provides 2025 Outlook | Valneva SE

Shareholding declaration Valneva SE - January 2025 | Valneva SE

Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ® | Valneva SE

Valneva Reports Positive Phase 2 Results in Children for its Chikungunya Vaccine and Announces Phase 3 Dose Decision | Valneva SE

VALNEVA Declaration of shares and voting rights: December 31, 2024 | Valneva SE

Valneva Successfully Expands Access to Asia for its Chikungunya Vaccine with Serum Institute of India | Valneva SE

VALNEVA - Declaration of shares and voting rights: November 30, 2024 | Valneva SE

Valneva Announces Peer-Reviewed Publication on the Global Health and Economic Burden of Chikungunya in The British Medical Journal | Valneva SE

Valneva Reports Positive Three-Year Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® | Valneva SE

Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2 | Valneva SE

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences | Valneva SE

Valneva Reports Nine-Month 2024 Financial Results and Provides Corporate Updates | Valneva SE

VALNEVA - Declaration of shares and voting rights: October 31, 2024 | Valneva SE

Valneva and LimmaTech Awarded FDA Fast Track Designation for Tetravalent Shigella Vaccine Candidate S4V | Valneva SE

Valneva Hosts Investor Day in New York City | Valneva SE

Valneva SE - Declaration of shares and voting rights - September 30, 2024 | Valneva SE

Valneva to Host Investor Day in New York on Thursday, October 10, 2024 at 10:00 AM ET | Valneva SE

Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada | Valneva SE

Valneva Announces the Success of its Private Placement Raising approximately €60 Million | Valneva SE

Valneva Announces the Launch of a Private Placement of Ordinary Shares for Approximately 60 Million Euros | Valneva SE